The Role and Impact of Minimal Residual Disease in NSCLC.
Daniele FrisoneAlex FriedlaenderAlfredo AddeoPublished in: Current oncology reports (2021)
Recent studies using ctDNA in NSCLC but also in other types of cancer found strong correlations between the presence of ctDNA and the risk of disease progression or death after curative intent, despite current technical difficulties in performing this analysis (high sensitivity and specificity required). Evaluation of MRD in NSCLC, especially through ctDNA, could be an important point in future trial designs and could permit a more "targeted" adjuvant treatment.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- circulating tumor
- brain metastases
- papillary thyroid
- clinical trial
- early stage
- study protocol
- phase iii
- epidermal growth factor receptor
- squamous cell
- rectal cancer
- phase ii
- circulating tumor cells
- cancer therapy
- randomized controlled trial
- cell free
- case control
- prognostic factors
- young adults
- childhood cancer